Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Hearing Canaccord Reiterates Buy Rating, $45 Price Target On Trevare Therapeutics; Calls PROTECT Data 'A Best-Case Scenario'


Benzinga | Aug 16, 2021 01:12PM EDT

Hearing Canaccord Reiterates Buy Rating, $45 Price Target On Trevare Therapeutics; Calls PROTECT Data 'A Best-Case Scenario'






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC